Susceptibility of Candida Blood Isolates to Fluconazole (FLU) and Voriconazole (VOR) in Russia.

A. VESELOV 1, G. KLIASOVA 2, E. AGAPOVA 3, I. MULTIKH 4, N. KLIMKO5, S. ROZANOVA 6, O. KRETCHIKOVA 1, N. DMITRIEVA 7, V. ILYINA 8, L. STRATCHOUNSKI 1;

Author address: 

1Inst. of Antimicrobial Chemotherapy, Smolensk, Russian Federation, 2Hematology Res. Ctr., Moscow, Russian Federation, 3Regional Pediatric Hosp., Irkutsk, Russian Federation, 4City Hosp. 8470;2, Krasnodar, Russian Federation, 5Res. Inst. of Med. My

Abstract: 

Background: To assess susceptibility of Candida blood isolates to FLU and VOR. Methods: Strains were tested with disk-diffusion method according M44-P NCCLS (CLSI) guidelines and assessed with BIOMIC® system within ARTEMIS Disk study. For VOR preliminary breakpoints were used to stratify strains between susceptible (S), susceptible dose-depended (SDD) and resistant (R) categories. Results: A total of 131 Candida blood isolates were tested in 2003-2005 period. The major tested species were as follows: C.albicans 46 (35.1%), C.parapsilosis 25 (19.1%) and Candida spp. 17 (13%). The main types of departments the strains were gathered from were: therapy (42.7%), surgical ICU (12.2%), hematology/oncology and medical ICU (both 11.5%). The susceptibility data are presented in Table 1. Table 1. Susceptibility data for FLU and VOR. Conclusions: FLU and VOR are highly active against main causative agent - C.albicans. C.glabrata is the least susceptible species among Candida genus both for FLU and VOR. Against C.krusei VOR shows high activity in contrast to FLU.
2006

abstract No: 

M-1593

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th